Skip to content

CNBX PHARMACEUTICALS INC.: 10-Q filed 2025-07-14

What CNBX PHARMACEUTICALS INC. reported in its quarterly report filed 2025-07-14 (fiscal Q3 2025): 28 published measures, 86 facts as tagged in accession 0001683168-25-005075.

This filing

Form
10-Q (quarterly report)
Filed
2025-07-14
Fiscal period
fiscal Q3 2025
Accession
0001683168-25-005075 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All CNBX PHARMACEUTICALS INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2025-05-3118,615USD
At 2024-08-3131,383USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2025-05-31-2,537,405USD
At 2025-02-28-2,570,480USD
At 2024-08-31-2,479,980USD
At 2024-05-31-2,454,371USD
At 2024-02-29-2,358,534USD
At 2023-08-31-2,017,289USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2025-05-3113,648USD
At 2024-08-3126,416USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2025-03-01 to 2025-05-31-59,727USD92
2024-09-01 to 2025-05-31-163,867USD273
2024-03-01 to 2024-05-31-130,632USD92
2023-09-01 to 2024-05-31-634,614USD274

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2024-09-01 to 2025-05-31-142,760USD273
2023-09-01 to 2024-05-31-196,019USD274

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2025-03-01 to 2025-05-310USD92
2024-09-01 to 2025-05-310USD273
2024-03-01 to 2024-05-310USD92
2023-09-01 to 2024-05-31130,074USD274

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2024-09-01 to 2025-05-31129,992USD273
2023-09-01 to 2024-05-3126,252USD274

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2024-09-01 to 2025-05-310USD273
2023-09-01 to 2024-05-31113,477USD274

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2025-05-31-25,118,267USD
At 2024-08-31-24,954,400USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2025-03-01 to 2025-05-3142,597,394shares92
2024-09-01 to 2025-05-3135,475,271shares273
2024-03-01 to 2024-05-3131,111,352shares92
2023-09-01 to 2024-05-3129,964,272shares274

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2025-03-01 to 2025-05-3142,597,394shares92
2024-09-01 to 2025-05-3135,475,271shares273
2024-03-01 to 2024-05-3131,111,352shares92
2023-09-01 to 2024-05-3129,964,272shares274

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2025-03-01 to 2025-05-310USD/shares92
2024-09-01 to 2025-05-310USD/shares273
2024-03-01 to 2024-05-310USD/shares92
2023-09-01 to 2024-05-31-0.02USD/shares274

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2025-03-01 to 2025-05-310USD/shares92
2024-09-01 to 2025-05-310USD/shares273
2024-03-01 to 2024-05-310USD/shares92
2023-09-01 to 2024-05-31-0.02USD/shares274

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2025-05-310USD
At 2024-08-310USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2024-09-01 to 2025-05-310USD273
2023-09-01 to 2024-05-31104,745USD274

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2025-03-01 to 2025-05-31-40,380USD92
2024-09-01 to 2025-05-31-141,960USD273
2024-03-01 to 2024-05-31-152,278USD92
2023-09-01 to 2024-05-31-530,606USD274

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2025-05-3118,615USD
At 2024-08-3131,383USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2025-05-312,556,020USD
At 2024-08-312,511,363USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2025-03-01 to 2025-05-3140,380USD92
2024-09-01 to 2025-05-31141,960USD273
2024-03-01 to 2024-05-31152,278USD92
2023-09-01 to 2024-05-31660,680USD274

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2025-03-01 to 2025-05-310USD92
2024-09-01 to 2025-05-310USD273
2024-03-01 to 2024-05-3142,884USD92
2023-09-01 to 2024-05-31268,722USD274

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2025-05-3192,511,352shares
At 2024-08-3131,111,352shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2025-05-3113,648USD
At 2024-08-3126,416USD
At 2024-05-3173,406USD
At 2023-08-31129,696USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2025-05-3122,571,611USD
At 2024-08-3122,471,309USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2025-05-314,967USD
At 2024-08-314,967USD

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2025-03-01 to 2025-05-31-59,727USD92
2024-09-01 to 2025-05-31-163,867USD273
2024-03-01 to 2024-05-31-130,632USD92
2023-09-01 to 2024-05-31-634,614USD274

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2025-03-01 to 2025-05-3140,380USD92
2024-09-01 to 2025-05-31141,960USD273
2024-03-01 to 2024-05-31109,394USD92
2023-09-01 to 2024-05-31391,958USD274

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2024-09-01 to 2025-05-310USD273
2023-09-01 to 2024-05-3172,320USD274

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

PeriodValueUnitDays
2025-03-01 to 2025-05-31-19,347USD92
2024-09-01 to 2025-05-31-21,907USD273
2024-03-01 to 2024-05-3121,646USD92
2023-09-01 to 2024-05-31-15,074USD274

Inspect the source

Entity
CNBX PHARMACEUTICALS INC. / CIK 0001343009
Captured
2026-09-20T07:54:32.519Z
SEC response SHA-256
915b78bb9f3d1ecdaff39577a9e5db4b6d0b32a87b795bd1dd92ab6d7b14ac19

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001343009.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))